<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Sun</title>
	<atom:link href="http://www.tapanray.in/tag/sun/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma &amp; Healthcare: Where The Healers Turn Looters?</title>
		<link>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-healthcare-where-the-healers-turn-looters</link>
		<comments>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/#comments</comments>
		<pubDate>Mon, 24 Nov 2014 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[300 doctors]]></category>
		<category><![CDATA[Ahmedabad]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clothing]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[healers]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[looters]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Octreotide]]></category>
		<category><![CDATA[Octride]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandostatin]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sheep]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tata]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Wolf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6221</guid>
		<description><![CDATA[Two news reports of the last week, though no longer shocking, made me think exactly the same way as the headline of this article epitomizes. These reports are not just two isolated instances, but an integral part of a similar &#8230; <a href="http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective</title>
		<link>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective</link>
		<comments>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/#comments</comments>
		<pubDate>Mon, 29 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Bureau]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global. world]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[ramparts. red fort]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sell]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6039</guid>
		<description><![CDATA[In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in &#8230; <a href="http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs From The Same Indian Plant: Safe For Europe, Unsafe For America, Why?</title>
		<link>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why</link>
		<comments>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/#comments</comments>
		<pubDate>Mon, 09 Jun 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[conspiracy]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plant]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[unsafe]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[why]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5493</guid>
		<description><![CDATA[Good number of stories on US-FDA banning several drug manufacturing facilities of major domestic players of India over serious quality related issues, have been doing the rounds since about a year and almost at a regular interval. The quagmire has &#8230; <a href="http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Sun Pharma Sailing In The Same Boat As Ranbaxy?</title>
		<link>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy</link>
		<comments>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/#comments</comments>
		<pubDate>Wed, 21 May 2014 07:57:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[boat]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Chouhan]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[SEBI]]></category>
		<category><![CDATA[Sikri]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vadodara]]></category>
		<category><![CDATA[Vod]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5420</guid>
		<description><![CDATA[A ‘Warning Letter’ of May 7, 2014 from the USFDA to Sun Pharmaceuticals &#8211; the no.1 pharma major by market capitalization in India has nailed its Karkhadi, Vadodara, Gujarat based plant in India for similar data deletions as found at &#8230; <a href="http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-sun-pharma-sailing-in-the-same-boat-as-ranbaxy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Takeover Magician To Tango Again On A Bold New ‘Sunny’ Tune</title>
		<link>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune</link>
		<comments>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/#comments</comments>
		<pubDate>Mon, 14 Apr 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Dilip]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[magician]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Shanghvi]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[sunny]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[takeover]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wand]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5240</guid>
		<description><![CDATA[The consolidation process of the Indian pharmaceutical industry continues in its own pace. Most recently, the homegrown pharma takeover magician is all set to tango yet again with a bold ‘Sunny’ tune. The low profile creator of high value ‘Sun &#8230; <a href="http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Loss of Ranbaxy, Gain of Big Pharma…And Two Intriguing Coincidences</title>
		<link>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences</link>
		<comments>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/#comments</comments>
		<pubDate>Mon, 17 Mar 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[coincidences]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[double]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hypothesis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Machiavellian]]></category>
		<category><![CDATA[murkier]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whammy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5096</guid>
		<description><![CDATA[In March 2014, the largest pharma player of India by market capitalization, Sun Pharma, became the latest of the large Indian pharma exporters facing the US-FDA ‘Import Ban’ for drugs manufactured at its Gujarat-based plant. This news came as a &#8230; <a href="http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just Born A Pharma Goliath: Would India Be Impacted?</title>
		<link>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-born-a-pharma-goliath-would-india-be-impacted</link>
		<comments>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/#comments</comments>
		<pubDate>Mon, 03 Mar 2014 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actavis]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chilcott]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Goliath]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seksharia]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[super]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[Watson]]></category>
		<category><![CDATA[Zentiva]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5030</guid>
		<description><![CDATA[Just born a potential pharma Goliath, as Actavis &#8211; the Dublin-based one of the largest global generic drug makers, in its biggest ever purchase, acquires New York based R&#38;D based pharma major &#8211; Forest Laboratories, for a whopping US$ 25 billion. &#8230; <a href="http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Force Multiplier: An &#8220;Armageddon&#8221;: A Contender for Supremacy in the Generic Pharma World</title>
		<link>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world</link>
		<comments>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/#comments</comments>
		<pubDate>Mon, 22 Apr 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ANDAa]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Armageddon]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[contender]]></category>
		<category><![CDATA[defend]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[DMFs]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fastest]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guardian]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringing]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[multiplier]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[supremacy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Taro]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[triggering]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UK-MHRA]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2193</guid>
		<description><![CDATA[It is very important for any country to ensure access to most appropriate medicines for the patients as and when they require. In many disease areas such access can be remarkably improved through affordable generic drugs, which offer significant savings &#8230; <a href="http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
